slc35a5 Antibody

What is SLC35A5 and what cellular functions have been identified?

SLC35A5 (Solute Carrier Family 35, Member A5) is a member of the SLC35A protein subfamily comprising nucleotide sugar transporters. The protein is localized in the Golgi apparatus, specifically co-localizing with both cis and trans cisternae of the Golgi apparatus . While its complete function remains to be fully characterized, research using CRISPR/Cas9-mediated gene knockout has revealed potential roles in nucleotide sugar transport. Specifically, SLC35A5 gene inactivation has been associated with decreased transport of UDP-glucuronic acid (UDP-GlcA), UDP-N-acetylglucosamine (UDP-GlcNAc), and UDP-N-acetylgalactosamine (UDP-GalNAc) into the Golgi apparatus . Additionally, the knockout has shown a slight increase in chondroitin sulfate proteoglycan levels, suggesting a role in proteoglycan synthesis regulation .

What are the optimal applications for SLC35A5 antibodies in research?

SLC35A5 antibodies have been validated primarily for Western Blotting (WB) and Immunohistochemistry (IHC) applications . For immunohistochemistry, these antibodies have been validated on panels of formalin-fixed, paraffin-embedded (FFPE) human tissues after heat-induced antigen retrieval in pH 6.0 citrate buffer . The antibodies work effectively in both standard IHC protocols and paraffin-embedded section applications (IHC-P). Western blotting applications typically involve using cell lysates as positive controls to confirm specificity . Some antibodies have also been validated for additional applications like ELISA, though this is less common among commercially available options .

What species reactivity can be expected from SLC35A5 antibodies?

SLC35A5 antibodies show broad cross-reactivity across multiple species due to the high conservation of the protein sequence. Available antibodies typically react with human, mouse, rat, cow, dog, guinea pig, and horse SLC35A5 proteins with high specificity . Some antibodies also demonstrate reactivity with rabbit (93% sequence identity), zebrafish (84-85% sequence identity), and other mammals including bat, monkey, and pig . This cross-reactivity is particularly valuable for comparative studies across different model organisms. Researchers should verify the predicted reactivity by BLAST analysis for their specific species of interest, as sequence identity can vary (typically ranging from 84-100% depending on the species) .

What are the recommended storage and handling procedures for SLC35A5 antibodies?

SLC35A5 antibodies are typically supplied in liquid format, with a 1x PBS buffer containing 0.09% (w/v) sodium azide and 2% sucrose as preservatives . For optimal stability and activity, researchers should avoid repeated freeze-thaw cycles, as this can lead to protein denaturation and loss of antibody function . It's advisable to aliquot the antibody upon receipt and store at -20°C for long-term preservation. When handling the antibody, note that it contains sodium azide, which is classified as a poisonous and hazardous substance requiring trained staff handling . For working solutions, storage at 4°C for short periods (1-2 weeks) is generally acceptable, but specific manufacturer guidelines should be followed for each product.

How can researchers validate the specificity of SLC35A5 antibodies in experimental systems?

Validating antibody specificity is critical for ensuring reliable experimental results. For SLC35A5 antibodies, a multi-tiered validation approach is recommended:

• CRISPR/Cas9 knockout controls: Generate SLC35A5 knockout cell lines using CRISPR/Cas9 technology as negative controls. In published research, PCR and RT-PCR have confirmed successful inactivation of the SLC35A5 gene through this method . The absence of signal in knockout cells provides strong evidence for antibody specificity.

• Epitope mapping confirmation: Verify that the antibody recognizes the expected region of the protein. For example, antibodies targeting the N-terminal region (AA 36-85) of SLC35A5 should be validated against this specific sequence .

• Western blotting profile analysis: Compare the molecular weight of detected bands against the expected size of SLC35A5 (approximately 424 amino acids) . Multiple bands may indicate splice variants or post-translational modifications.

• Co-localization studies: Confirm that the antibody-detected signal co-localizes with known Golgi markers. Research has shown that SLC35A5 co-localizes with both cis (using GM130 as marker) and trans (using syntaxin 16 as marker) Golgi cisternae .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm that this blocks detection, validating epitope-specific binding.

What methodologies can elucidate SLC35A5's role in nucleotide sugar transport?

SLC35A5's potential function in nucleotide sugar transport can be investigated using several complementary approaches:

• Golgi-enriched vesicle transport assays: Prepare Golgi-enriched vesicles from wild-type and SLC35A5 knockout cells to measure nucleotide sugar uptake. Research has demonstrated that SLC35A5 gene inactivation decreases UDP-GlcA transport by approximately 50% compared to wild-type cells, and also reduces UDP-GlcNAc and UDP-GalNAc Golgi uptake .

• Protein-protein interaction studies: Employ FLIM/FRET (Fluorescence Lifetime Imaging Microscopy/Förster Resonance Energy Transfer) analysis to investigate potential interactions between SLC35A5 and other SLC35A family members. This approach has been successfully used for analyzing interactions between nucleotide sugar transporters .

• Reconstitution experiments: Express SLC35A5 in liposomes to directly measure its transport activity for different nucleotide sugars.

• Metabolic labeling: Use radioactively or fluorescently labeled sugar precursors to track changes in glycan synthesis in the presence or absence of SLC35A5.

• Glycomic analysis: Apply mass spectrometry-based glycomic profiling to identify specific alterations in glycosylation patterns resulting from SLC35A5 deficiency or overexpression.

How does SLC35A5 knockout affect cellular glycosylation patterns?

Studies using CRISPR/Cas9-mediated knockout of SLC35A5 have revealed selective effects on glycosylation pathways:

• N- and O-glycans: Research has shown that SLC35A5 knockout in HepG2 cells does not affect N- or O-glycan profiles, suggesting that other transporters may compensate for its loss in these pathways .

• Glycolipids: No significant changes in glycolipid composition have been observed in SLC35A5-deficient cells .

• Proteoglycans: SLC35A5 knockout results in a slight increase in chondroitin-4-sulfate levels, as confirmed by both immunofluorescence and Western blotting analysis using antibodies against chondroitin sulfate A . This suggests a specific role in proteoglycan synthesis or turnover.

• Nucleotide sugar pools: SLC35A5 deficiency leads to decreased UDP-GlcA, UDP-GlcNAc, and UDP-GalNAc transport into the Golgi apparatus, which may affect specific glycosylation pathways depending on these substrates .

These findings suggest that SLC35A5 may have a specialized function in particular glycosylation pathways rather than broadly affecting all glycoconjugate synthesis.

What techniques are optimal for studying SLC35A5 subcellular localization?

To accurately determine SLC35A5 subcellular localization, researchers can employ the following methodological approaches:

• Immunofluorescence co-localization: Use SLC35A5 antibodies in combination with established organelle markers. Research has successfully employed this approach with the following markers :

  • Calnexin for endoplasmic reticulum

  • GM130 for cis-Golgi cisternae

  • Syntaxin 16 for trans-Golgi cisternae

• Subcellular fractionation: Isolate Golgi fractions and other organelles by differential centrifugation followed by Western blotting to detect SLC35A5 distribution.

• Epitope-tagged expression systems: Generate cells expressing HA-tagged SLC35A5 (as demonstrated in published research using pSelect-A5-HA plasmid) for detection with anti-HA antibodies when direct SLC35A5 antibodies may have limitations .

• Super-resolution microscopy: Employ techniques like STORM or STED to precisely map SLC35A5 localization within the Golgi subcompartments at nanometer resolution.

• Electron microscopy: Use immunogold labeling with SLC35A5 antibodies for ultrastructural localization studies.

When employing these techniques, researchers should include appropriate controls for antibody specificity, including SLC35A5 knockout cells as negative controls .

What is known about SLC35A5 expression in cancer and other pathological conditions?

Current research on SLC35A5 expression in disease contexts reveals:

• Breast cancer: Transcriptomic analyses show that SLC35A5 transcript levels are down-regulated in breast cancer tissues compared to healthy controls . This contrasts with SLC35A2 and SLC35A3, which are overexpressed in breast cancer tissues .

• Triple-negative breast cancer (TNBC): Cell line analyses using the Cancer Cell Line Encyclopedia (CCLE) have demonstrated high expression of SLC35A5 in TNBC cell lines including HCC1395, HCC1187, and MDAMB436 . This suggests potential tissue-specific or context-dependent regulation of SLC35A5 expression.

• Other SLC35A family members in disease: While specific information about SLC35A5 in other diseases is limited, related family members have established roles in pathological conditions. For instance, mosaic variants of SLC35A2 cause congenital disorders of glycosylation (CDG) with neurological impairments .

• Drug resistance: Some SLC transporters play roles in resistance to cytotoxic medicines. While direct evidence for SLC35A5 is lacking, related transporters SLC35A2 and SLC38A5 are involved in sensitivity to cisplatin .

Researchers investigating SLC35A5 in disease contexts should consider these differential expression patterns and potential functional implications.

How can SLC35A5 antibodies be optimized for immunohistochemistry in pathological specimens?

For optimal immunohistochemical detection of SLC35A5 in clinical and pathological specimens, researchers should consider:

How can researchers address non-specific binding issues with SLC35A5 antibodies?

When encountering non-specific binding with SLC35A5 antibodies, consider the following methodological solutions:

• Optimize blocking conditions: Increase blocking time or test alternative blocking agents (BSA, normal serum, commercial blockers) compatible with your detection system.

• Antibody dilution optimization: Test a range of dilutions to identify the optimal concentration that maximizes specific signal while minimizing background.

• Increase washing stringency: Add additional washing steps or include low concentrations of detergents (0.1-0.3% Triton X-100 or Tween-20) in washing buffers.

• Antibody pre-adsorption: For tissues with high endogenous biotin or other sources of cross-reactivity, pre-adsorb the primary antibody with the relevant tissue lysate.

• Alternative antibody selection: Consider antibodies raised against different epitopes of SLC35A5, as some regions may be more prone to non-specific interactions .

• Monoclonal vs. polyclonal consideration: Current commercially available SLC35A5 antibodies are primarily rabbit polyclonals . If non-specific binding persists, monoclonal antibodies may offer improved specificity, though availability may be limited.

• Validation with knockout controls: Always compare staining patterns with SLC35A5-deficient samples to distinguish specific from non-specific signals .

What approaches can resolve contradictory data about SLC35A5 function and expression?

When faced with conflicting results regarding SLC35A5 expression or function, researchers should consider:

• Cell type and tissue specificity: Expression patterns may vary significantly across different cell types. For example, SLC35A5 is downregulated in breast cancer tissues but highly expressed in certain TNBC cell lines .

• Antibody epitope considerations: Different antibodies targeting distinct regions of SLC35A5 may yield varying results due to epitope accessibility, post-translational modifications, or protein interactions .

• Redundancy with other transporters: Functional redundancy with other SLC35A family members may mask phenotypes in certain experimental systems, requiring combinatorial knockdown approaches.

• Quantification method standardization: Ensure consistent quantification methods when comparing SLC35A5 levels across studies (e.g., normalization to housekeeping proteins, standardized exposure times).

• Genetic background effects: When using knockout models, background strain differences can influence phenotypic outcomes.

• Technical validation across platforms: Verify findings using orthogonal techniques:

  • Protein expression: Compare Western blot, immunofluorescence, and immunohistochemistry results

  • mRNA expression: Validate with qRT-PCR, RNA-seq, and in situ hybridization

  • Functional assays: Combine genetic disruption with biochemical transport assays

• Reproducibility assessment: Evaluate whether conflicting findings might result from biological variability versus methodological differences by replicating key experiments under standardized conditions.

What emerging techniques might advance understanding of SLC35A5 function and regulation?

Several cutting-edge approaches hold promise for elucidating SLC35A5 biology:

• CRISPR-based screens: Conduct genome-wide CRISPR screens in SLC35A5-deficient backgrounds to identify genetic interactions and compensatory pathways.

• Proximity labeling proteomics: Apply BioID or APEX2 tagging to SLC35A5 to identify proximal interacting proteins within the Golgi environment.

• Single-cell glycomics: Develop and apply single-cell glycan analysis methods to reveal cell-to-cell variation in glycosylation responses to SLC35A5 modulation.

• Structural biology approaches: Pursue cryo-EM or X-ray crystallography studies of SLC35A5 to understand its transport mechanism and substrate specificity.

• In vivo models with tissue-specific disruption: Generate conditional knockout mouse models to investigate tissue-specific functions of SLC35A5.

• Glycan-focused CRISPR screens: Design screens specifically targeting glycosylation pathways to position SLC35A5 within functional networks.

• Multi-omics integration: Combine transcriptomics, proteomics, glycomics, and metabolomics data to build comprehensive models of SLC35A5 function in cellular metabolism.

• Live-cell imaging of nucleotide sugar dynamics: Develop fluorescent nucleotide sugar analogs to visualize transport in real-time in living cells.

How can researchers effectively study interactions between SLC35A5 and other SLC family members?

To investigate potential functional interactions between SLC35A5 and other transporters, researchers should consider:

• FLIM/FRET analysis: This approach has been successfully employed to study interactions between nucleotide sugar transporters and could be applied to investigate potential interplay between SLC35A5 and other SLC35A subfamily members .

• Co-immunoprecipitation studies: Use SLC35A5 antibodies to pull down protein complexes and identify interacting partners through mass spectrometry.

• Bimolecular fluorescence complementation (BiFC): Split fluorescent protein assays can visualize protein-protein interactions in cellular contexts.

• Combinatorial genetic approaches: Generate double or triple knockout cell lines targeting multiple SLC transporters to reveal functional redundancy or synergy.

• Reconstitution systems: Reconstitute purified transporters in liposomes to test direct functional interactions in a controlled membrane environment.

• Protein fragment complementation assays: Apply split-enzyme reporters (luciferase, β-lactamase) to quantitatively assess protein interactions in living cells.

• Cross-linking mass spectrometry: Use chemical cross-linkers to stabilize transient interactions followed by mass spectrometry identification of cross-linked peptides.

Previous research has established that nucleotide sugar transporters can form both homomers and interact with other transporters, providing a foundation for investigating SLC35A5's potential interaction network .